Results 61 to 70 of about 690 (120)
Background/Objectives: The rise of virtual bioequivalence studies has transformed the pharmaceutical landscape, enabling more efficient drug development processes. This systematic review aims to explore advancements in Physiologically-Based Pharmacokinetic (PBPK) modeling, its regulatory implications, and its role in achieving virtual bioequivalence ...
Nasser Alotaiq, Doni Dermawan
openaire +1 more source
Tofacitinib is a potent, selective inhibitor of the Janus kinase (JAK) family of kinases with a high degree of selectivity within the human genome's set of protein kinases. Currently approved formulations for tofacitinib citrate are immediate‐release (IR) tablets, modified‐release (MR) tablets, and IR solution.
Vivek Purohit +10 more
openaire +2 more sources
Introduction. Sorafenib is an antineoplastic drug belonging to class IIc according to the biopharmaceutical classification system (BCS) due to the presence of both acidic and basic properties.
A. V. Suvorova +6 more
doaj +1 more source
The vaginal route of administration enables convenient local and systemic drug delivery with the avoidance of hepatic first-pass metabolism. Considering the clinical advantages of vaginal delivery, development of physiologically based pharmacokinetic (PBPK) models of vaginal absorption to inform drug and formulation development is deemed valuable.
Kanika Thakur +8 more
openaire +3 more sources
The aim of the present study was to assess the accuracy of the PBPK model in predicting the pharmacokinetic behavior of weakly acidic BCS class II drugs in humans through a multipronged approach of in vitro dissolution, in vivo studies, and in silico simulations.
Chenxia, Bai +4 more
openaire +2 more sources
Virtual Trial Comparisons and Bioequivalence Assessment: From Data-Based to Probabilistic Assessment
The recent emergence of virtual comparative trials, in particular for virtual bioequivalence (VBE) assessment, implies a formalization of their analyses. In recent VBE assessments, pharmacokinetic models informed with in vitro data and verified with small clinical trials data were used to simulate otherwise unfeasibly large trials. Simulated VBE trials
Brochot, Céline, Bois, Frederic Yves
openaire +1 more source
We show that correct statistical inference from simulated virtual clinical trials requires a Bayesian framework. Simulating frequentist test procedures degrades the prior information contained in the model. We demonstrate the application of a Bayesian workflow to PBPK-simulated virtual bioequivalence trials.
openaire +3 more sources
Model-Integrated Bioequivalence (MIBE) in Generic Drug Research: Can We Ease the Bioequivalence Burden? [PDF]
Kollipara S +3 more
europepmc +1 more source
Guiding a Diclofenac Sodium Dual-Release Sustained Formulation Development Through In Vitro-In Vivo Relationship Based on Physiologically Based Pharmacokinetics. [PDF]
Wang Q +7 more
europepmc +1 more source
Effectiveness of virtual simulation-based pre-learning and the mediating role of metacognition in pharmacokinetics laboratory education. [PDF]
Hu X, Liu J, Wang J.
europepmc +1 more source

